Ceritinib: new treatment for ALK-positive non-small cell lung cancer

Zykadia (ceritinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

Ceritinib is a selective oral ALK inhibitor.  | SCIENCE PHOTO LIBRARY
Ceritinib is a selective oral ALK inhibitor. | SCIENCE PHOTO LIBRARY

Ceritinib inhibits autophosphorylation of ALK, ALK-mediated phosphorylation of downstream signalling proteins and proliferation of ALK-dependent cancer cells both in vitro and in vivo.

Clinical studies

Ceritinib was evaluated in two single-arm studies in patients with ALK-positive NSCLC previously treated with an ALK inhibitor. Investigators used the overall response rate (ORR) as the primary efficacy endpoint.

Further information
View Zykadia drug record
Summary of Product Characteristics
Manufacturer: Novartis

In the first (phase I) study in patients who had previously received treatment with crizotinib (Xalkori) (n=80), the ORR was 56% (95% CI 45–67) and the median progression-free survival (PFS) was 6.9 months (95% CI 5.3–8.8).

The second (phase II) study evaluated the efficacy and safety of ceritinib in 140 patients who had been previously treated with 1-3 lines of cytotoxic chemotherapy followed by crizotinib, and who had then progressed on crizotinib. ORR with ceritinib was 37.1% (95% CI 29.145.7) and median PFS was 5.7 months (95% CI 5.3–7.4).

The most commonly reported adverse effects (≥10%) of ceritinib were GI upset, fatigue, abnormal LFT results, anorexia, raised blood creatinine, rash and anaemia.

Conditional approval

Zykadia has been authorised under the 'conditional approval' scheme, meaning further evidence of clincial benefit from the ongoing second study, as well as a phase III study comparing ceritinib with other chemotherapy, is required. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...

New MIMS table helps prescribers choose asthma inhalers

New MIMS table helps prescribers choose asthma inhalers

Prescribers can now turn to a handy MIMS comparison...